Gut dysbiosis contributes to Parkinson's disease (PD) pathogenesis. Gastrointestinal disturbances in PD patients, along with gut leakage and intestinal inflammation, take place long before motor disorders. However, it remains unknown what bacterial species in gut microbiomes play the key role in driving PD pathogenesis. Here we show that Helicobacter hepaticus (H. hepaticus), abundant in gut microbiota from rotenone-treated human α-Synuclein gene (SNCA) transgenic mice and PD patients, initiates α-Synuclein pathology and motor deficits in an AEP-dependent manner in SNCA mice. Chronic Dextran sodium sulfate (DSS) treatment, an inflammatory inducer in the gut, activates AEP (asparagine endopeptidase) that cleaves α-Synuclein N103 and triggers its aggregation, promoting inflammation in the gut and the brain and motor defects in SNCA mice. PD fecal microbiota transplant or live H. hepaticus administration into antibiotics cocktail (Abx)-pretreated SNCA mice induces α-Synuclein pathology, inflammation in the gut and brain, and motor dysfunctions, for which AEP is indispensable. Hence, Helicobacter hepaticus enriched in PD gut microbiomes may facilitate α-Synuclein pathologies and motor impairments via activating AEP.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41380-022-01910-2DOI Listing

Publication Analysis

Top Keywords

helicobacter hepaticus
12
snca mice
12
motor disorders
8
parkinson's disease
8
gut
8
gut microbiomes
8
α-synuclein pathology
8
inflammation gut
8
gut brain
8
brain motor
8

Similar Publications

Colorectal cancer (CRC) is one of the most common cancers worldwide. The standard CRC chemo drug, 5-Fluorouracil (5-FU), has a poor response rate and chemoresistance, prompting the need for a more effective and affordable treatment. In this study, we aimed to evaluate whether Prohep, a novel probiotic mixture, would alleviate azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colorectal tumorigenesis and enhance 5-FU efficacy and its mechanism.

View Article and Find Full Text PDF
Article Synopsis
  • * Mice fed a methionine-choline deficient diet to induce NASH were treated with rifaximin, which significantly reduced liver fat, inflammation, and fibrosis.
  • * Rifaximin was found to change gut microbiota and inhibit the intestinal DCA-Fxr-Hnf1α signaling pathway, suggesting its potential for treating NASH clinically.
View Article and Find Full Text PDF
Article Synopsis
  • Obesity is linked to issues like gut microbiota imbalance, inflammation, and intestinal barrier dysfunction, and flavonoids like hesperidin may provide safe anti-obesity solutions.
  • In experiments with high-fat diet (HFD)-fed mice, hesperidin treatment reduced body weight, fat accumulation, inflammation markers, and improved gut health, showing a dose-dependent effect.
  • Both hesperidin and fecal microbiota transplantation (FMT) successfully reduced body weight and addressed HFD-related disorders by altering gut microbiota composition.
View Article and Find Full Text PDF

Heme trafficking is essential for cellular function, yet mechanisms of transport and/or heme interaction are not well defined. The System I and System II bacterial cytochrome c biogenesis pathways are developing into model systems for heme trafficking due to their functions in heme transport, heme stereospecific positioning, and mediation of heme attachment to apocytochrome c. Here we focus on the System II pathway, CcsBA, that is proposed to be a bi-functional heme transporter and holocytochrome c synthase.

View Article and Find Full Text PDF

Objectives: We here assessed whether typical pathogens of laboratory mice affect the development of diet-induced obesity and glucose intolerance, and whether colonization affects the efficacy of the GLP-1R agonist liraglutide and of the GLP-1/GIP co-agonist MAR709 to treat obesity and diabetes.

Methods: Male C57BL/6J mice were experimentally infected with Helicobacter hepaticus, Rodentibacter pneumotropicus and Staphylococcus aureus and compared to a group of uninfected specific and opportunistic pathogen free (SOPF) mice. The development of diet-induced obesity and glucose intolerance was monitored over a period of 26 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!